Ann Marie Craig

Dr. Craig completed her BSc in biochemistry at Carleton University and received her PhD from University of Western Ontario. Prior to obtaining her first academic faculty position, she was a postdoctoral fellow in the field of neuroscience at the National Institutes of Health, USA and at the University of Virginia.

Specialized connections between nerve cells, called synapses, are the basic units of communication in the brain. We study how brain cells make synaptic connections and how these connections are altered in neuropsychiatric disorders. We use a range of approaches from molecular manipulations in neuron cultures to electro-physiological recording and serial block face scanning electron microscopy of neural circuits in genetically targeted mouse models to expansion microscopy of human clinical samples. Further, we are working to develop targeted reagents to correct synaptic imbalances in autism, schizophrenia, epilepsy, and Alzheimer’s disease.

To highlight a few examples of our recent research, among the synaptic organizers we identified, LRRTMs are now studied as central to the process of long term potentiation which is thought to be a cellular basis for learning and memory. Our discovery of suppressors of synaptic organizing proteins led to the characterization of MDGA2 haploinsufficient mice with altered excitation/inhibition balance as a new model for autism (https://can-acn.org/ubc-researchers-may-have-found-how-electrical-volume…). In another combined genetic and proteomics screen to identify novel GABA receptor interacting proteins, we identified an unusual regulator that scales inhibitory synaptic strength, which could be harnessed to correct imbalances in excitation/inhibition. Recently, we discovered an essential role for a rare glycan modification in the canonical neurexin-neuroligin synaptic organizing complex implicated in autism and schizophrenia. Remarkably, mice lacking this single sugar modification on neurexin-1 have severe structural and functional deficits in hippocampal synapses and reduced survival. These findings reveal a new set of neurexin interacting proteins, another level of regulation through glycan fine structure, and a novel direction for therapeutic intervention. A current research focus is to understand the role of such post-transcriptional modifications of synaptic organizing complexes in brain development and to harness this knowledge to develop therapeutics for neuropsychiatric disorders. Another current project uses a novel expansion microscopy approach on clinical specimens towards understanding synaptic diversity and its role in epilepsy.

Source

Fellow of the Royal Society of Canada

Peer-reviewed publications